Cognition Therapeutics (NASDAQ:CGTX) & Moderna (NASDAQ:MRNA) Head-To-Head Survey

Moderna (NASDAQ:MRNAGet Rating) and Cognition Therapeutics (NASDAQ:CGTXGet Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Institutional & Insider Ownership

60.8% of Moderna shares are owned by institutional investors. Comparatively, 23.1% of Cognition Therapeutics shares are owned by institutional investors. 17.3% of Moderna shares are owned by company insiders. Comparatively, 20.6% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Moderna and Cognition Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna 0 7 5 0 2.42
Cognition Therapeutics 0 0 3 0 3.00

Moderna presently has a consensus price target of $176.79, indicating a potential upside of 3.26%. Cognition Therapeutics has a consensus price target of $15.00, indicating a potential upside of 1,036.36%. Given Cognition Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Moderna.


This table compares Moderna and Cognition Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Moderna 55.00% 70.03% 45.09%
Cognition Therapeutics N/A -140.15% -43.56%

Earnings and Valuation

This table compares Moderna and Cognition Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Moderna $18.47 billion 3.56 $12.20 billion $27.64 6.19
Cognition Therapeutics N/A N/A -$11.72 million N/A N/A

Moderna has higher revenue and earnings than Cognition Therapeutics.


Moderna beats Cognition Therapeutics on 7 of the 10 factors compared between the two stocks.

About Moderna

(Get Rating)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Cognition Therapeutics

(Get Rating)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with's FREE daily email newsletter.